Efavirenz Plasma Concentrations and Cytochrome 2B6 Polymorphisms

被引:16
作者
Lindfelt, Tristan [2 ]
O'Brien, John [2 ]
Song, Jessica C. [1 ]
Patel, Rajul [1 ]
Winslow, Dean L. [3 ,4 ,5 ]
机构
[1] Univ Pacific, Dept Pharm Practice, Stockton, CA 95211 USA
[2] Santa Clara Valley Med Ctr, Dept Pharm, San Jose, CA 95128 USA
[3] Santa Clara Valley Med Ctr, Dept Med, San Jose, CA 95128 USA
[4] Santa Clara Valley Med Ctr, Div AIDS Med, San Jose, CA 95128 USA
[5] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA
关键词
cytochrome; 2B6; polymorphisms; efavirenz; CYP2B6; POLYMORPHISM; METABOLISM; ALLELES; PHARMACOKINETICS; INDIVIDUALS; VARIABILITY; POPULATIONS; PREVALENCE; GENDER;
D O I
10.1345/aph.1P141
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Interpatient variability in efavirenz concentrations may be due to CYP2B6 genetic polymorphisms. Efavirenz concentration and pharmacogenomic data are scarce in Latino patients. OBJECTIVE: To evaluate the difference in trough and midpoint efavirenz plasma concentrations between HIV-positive Latino and white patients. In addition, this study evaluated the association between efavirenz concentrations and CYP2B6 polymorphisms in Latino and white HIV-positive subjects. METHODS: This pilot study included 10 Latinos and 10 whites. Two efavirenz blood concentrations were determined: a trough and a midpoint. CYP2B6 genetic polymorphisms were analyzed at the 516 (G to T) and 785 (A to G) codons. The Mann-Whitney test was used to determine whether efavirenz concentrations varied with ethnicity. The Kruskal-Wallis test was used to determine whether efavirenz concentrations varied with CYP2B6 genetic polymorphisms. Efavirenz concentrations were expressed as medians (minimum, maximum). RESULTS: Midpoint concentrations were 1.58 mu g/mL (1.36, 6.02) and 3.14 mu g/mL (1.74, 7.72) for whites and Latinos, respectively (p < 0.05). Trough concentrations did not vary as a function of ethnicity. Ten percent of Latinos and whites tested positive for homozygous variants of CYP2B6-516 and CYP2B6-785. One white subject tested positive for the homozygous variant of CYP2B6-1459. Trough concentrations for 5167 516GT, and 516GG (wild type) were 5.13 mu g/mL (4.13, 6.12), 2.13 mu g/mL (1.33, 3.37), and 1.44 mu g/mL (0.59, 2.92), respectively (p < 0.05). Trough concentrations for 785GG, 785AG, and 785AA (wild type) were 5.12 mu g/mL (4.13, 6.12), 1.98 mu g/mL (1.33, 3.37), and 1.27 mu g/mL (0.59, 2.92), respectively (p < 0.05). None of the patients took concomitant medications that impacted CYP2B6 metabolism. CONCLUSIONS: Trough efavirenz concentrations were significantly higher in patients with the 785 (A to G) and 516 (G to T) variants. Midpoint efavirenz concentrations in Latinos were significantly higher than those of whites.
引用
收藏
页码:1572 / 1578
页数:7
相关论文
共 19 条
[1]  
[Anonymous], US QUICKFACTS
[2]  
*BRIST MYERS SQUIB, 2010, PRESCR INF SUST EF
[3]   Metabolism of efavirenz and 8-hydroxyefavirenz by P4502B6 leads to inactivation by two distinct mechanisms [J].
Bumpus, Namandje N. ;
Kent, Ute M. ;
Hollenberg, Paul F. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (01) :345-351
[4]   Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism [J].
Burger, D ;
van der Heiden, I ;
la Porte, C ;
van der Ende, M ;
Groeneveld, P ;
Richter, C ;
Koopmans, P ;
Kroon, F ;
Sprenger, H ;
Lindemans, J ;
Schenk, P ;
van Schaik, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) :148-154
[5]   THE PITTSBURGH SLEEP QUALITY INDEX - A NEW INSTRUMENT FOR PSYCHIATRIC PRACTICE AND RESEARCH [J].
BUYSSE, DJ ;
REYNOLDS, CF ;
MONK, TH ;
BERMAN, SR ;
KUPFER, DJ .
PSYCHIATRY RESEARCH, 1989, 28 (02) :193-213
[6]   Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro [J].
Desta, Zeruesenay ;
Saussele, Tanja ;
Ward, Bryan ;
Blievernicht, Julia ;
Li, Lang ;
Klein, Kathrin ;
Flockhart, DavidA ;
Zanger, Ulrich M. .
PHARMACOGENOMICS, 2007, 8 (06) :547-558
[7]   Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26 [J].
Gatanaga, Hiroyuki ;
Hayashida, Tsunefusa ;
Tsuchiya, Kiyoto ;
Yoshino, Munehiro ;
Kuwahara, Takeshi ;
Tsukada, Hiroki ;
Fujimoto, Katsuya ;
Sato, Isao ;
Ueda, Mikio ;
Horiba, Masahide ;
Hamaguchi, Motohiro ;
Yamamoto, Masahiro ;
Takata, Noboru ;
Kimura, Akiro ;
Koike, Takao ;
Gejyo, Fumitake ;
Matsushita, Shuzo ;
Shirasaka, Takuma ;
Kimura, Satoshi ;
Oka, Shinichi .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (09) :1230-1237
[8]  
Haas DW, 2004, AIDS, V18, P2391
[9]   Estimation of HIV incidence in the United States [J].
Hall, H. Irene ;
Song, Ruiguang ;
Rhodes, Philip ;
Prejean, Joseph ;
An, Qian ;
Lee, Lisa M. ;
Karon, John ;
Brookmeyer, Ron ;
Kaplan, Edward H. ;
McKenna, Matthew T. ;
Janssen, Robert S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :520-529
[10]   Hepatic CYP2B6 expression:: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (Constitutive Androstane Receptor) expression [J].
Lamba, V ;
Lamba, J ;
Yasuda, K ;
Strom, S ;
Davila, J ;
Hancock, ML ;
Fackenthal, JD ;
Rogan, PK ;
Ring, B ;
Wrighton, SA ;
Schuetz, EG .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03) :906-922